This table lists all the major pharma collaborations, acquisitions and mergers agreed during April 2014.
For an indepth analysis of these deals, read ‘Pharma deals during April 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| GSK/ Novartis | Acquisition | Oncology portfolio including pipeline products | 15,500 |
| Biomet/ Zimmer Holdings | Acquisition | Devices – Musculoskeletal/ Orthopaedics | 13,350 |
| Novartis/ GSK | Acquisition | Vaccines portfolio, excluding influenza business | 7,100 |
| Questcor/ Mallinckrodt | Acquisition | Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions | 5,600 |
| Novartis/ Eli Lilly | Acquisition | Animal Health franchise | 5,400 |
| Ranbaxy Laboratories/ Sun Pharmaceuticals | Acquisition | Generics including Lipitor, Nexium, Diovan | 3,200 |
| Furiex/ Forest Labs | Acquisition | IBS, eluxadoline, a mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of IBD (NDA-ready) | 1,460 |
| Insight Pharmaceuticals/ Prestige Brands | Acquisition | OTC – 30 brands Women’s Health and personal care products, including pregnancy testing; MONISTAT® vaginal anti-fungal | 750 |
| iPerian/ BMS | Acquisition | CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical) | 725 |
| Forma Therapeutics/ Celgene | R&D collaboration + options: to extend, license, acquire company | 3.5-year drug discovery collaboration covering a broad range of protein target families | 600 |
| Andromeda Biotech/ Hyperion Therapeutics | Acquisition | DiaPep277 24-amino acid peptide derived from human heat shock protein 60 (hsp60) to treat T1DM (p3) | 570 |
| Oryzon/ Roche (pRED) | Early stage drug research pact | Oncology – LSD1 inhibitors, Orphan cancer blocker ORY-1001 (p1/2a for acute myeloid leukaemia) | 521+ |
| Iquum/ Roche | Acquisition | Molecular Diagnostics – Laboratory-in-a-tube (Liat™) System | 450 |
| AccessClosure/ Cardinal Health | Acquisition |
Devices – Mynx vascular closure device |
320 |
| GSK/ Amgen | Termination | Prolia (denosumab) for osteoporosis in certain countries * | 275 |
| Sentinal Oncology/ Oncothyreon | Collaboration | Preclinical checkpoint kinase 1 (Chk1) programme | 174 |
| Aptiv Solutions/ ICON | Acquisition | CRO/ Adaptive Clinical Trials | 143.5 |
| California Stem Cell/ NeoStem | Acquisition | Stem cell immune-based therapy Melapuldencel-T, to treat metastatic melanoma (p2) | 124+ |
| New Wave Surgical/ Covidien | Acquisition | Device – D-HELP kit (to be re-named Clearify Visualization System) | 100+ |
| Agenus/ Merck & Co | Discovery collaboration/ licence | Immune checkpoint antibodies; 4-Antibody Retrocyte Display(R) platform | 100 |
| Silom Medical Company/ Actavis | Acquisition | Generics – 25 products in various dosage forms | 100 |
All deals are worldwide unless otherwise noted.
* Amgen will assume full marketing duties in areas including the EU, Switzerland, Norway, Russia and Mexico. GSK retains rights in Australia (bone) and countries such as China, Brazil, India and South Korea for other uses.